user

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

被引：25
|
作者：
Keir, Stephen T. [1 ]
Morton, Christopher L. [2 ]
Wu, Jianrong [2 ]
Kurmasheva, Raushan T. [3 ]
Houghton, Peter J. [3 ]
Smith, Malcolm A. [4 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[3] Nationwide Childrens Hosp, Columbus, OH USA
[4] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 03期
关键词：
developmental therapeutics; pazopanib; preclinical testing; MULTIKINASE ANGIOGENESIS INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; PHASE-II; RECURRENT; CARCINOMA; TRIAL;
D O I：
10.1002/pbc.24016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pazopanib is an oral angiogenesis inhibitor targeting vascular growth factor receptor-1, -2, and -3, platelet derived growth factor receptor-a, platelet derived growth factor receptor-beta, and KIT that has demonstrated activity against a variety of adult cancer xenografts. Pazopanib was tested against a panel of pediatric rhabdomyosarcoma and Ewing sarcoma xenografts at a dose of 108?mg/kg/day or 100?mg/kg twice daily, administered orally for 28 days. While no objective responses were observed, pazopanib induced statistically significant differences in event-free survival compared to controls in approximately one-half of the sarcoma xenograft models tested. Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay. Pediatr Blood Cancer 2012;59:586588. (c) 2011 Wiley Periodicals, Inc.
引用
收藏
页码：586 / 588
页数：3
相关论文
共 50 条
  • [41] Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Maris, John M.
    Lock, Richard
    Carol, Hernan
    Kurmasheva, Raushan T.
    Reynolds, C. Patrick
    Kang, Min H.
    Wu, Jianrong
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 58 (05) : 815 - 818
  • [42] Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program
    Lock, Richard
    Carol, Hernan
    Maris, John M.
    Kolb, E. Anders
    Gorlick, Richard
    Reynolds, C. Patrick
    Kang, Min H.
    Keir, Stephen T.
    Wu, Jianrong
    Purmal, Andrei
    Gudkov, Andrei
    Kurmashev, Dias
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (04)
  • [43] Initial testing by the Pediatric Preclinical Testing Program (PPTP) of the ATR Inhibitor VX-970 alone or in combination with cisplatin in pediatric solid tumor xenografts
    Houghton, P.
    Kang, M.
    Reynolds, C. P.
    Kurmasheva, R.
    Smith, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S49 - S49
  • [44] Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
    Kurmasheva, Raushan T.
    Sammons, Melissa
    Favours, Edward
    Wu, Jianwrong
    Kurmashev, Dias
    Cosmopoulos, Katherine
    Keilhack, Heike
    Klaus, Christine R.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (03)
  • [45] Initial Testing (Stage 1) of Glembatumumab Vedotin (CDX-011) by the Pediatric Preclinical Testing Program
    Kolb, E. Anders
    Gorlick, Richard
    Billups, Catherine A.
    Hawthorne, Thomas
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (10) : 1816 - 1821
  • [46] Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program
    Houghton, Peter J.
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Phelps, Doris
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Wozniak, Amy W.
    Gu, Yongchuan
    Wilson, William R.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2011, 57 (03) : 443 - 453
  • [47] Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)
    Smith, Malcolm A.
    Kang, Min
    Reynolds, Patrick C.
    Lock, Richard B.
    Carol, Hernan
    Gorlick, Richard
    Kolb, Anders E.
    Maris, John M.
    Keir, Stephen T.
    Billups, Catherine A.
    Kurmasheva, Raushan
    Houghton, Peter J.
    CANCER RESEARCH, 2015, 75
  • [48] Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Maris, John M.
    Lock, Richard B.
    Carol, Hernan
    Reynolds, C. Patrick
    Kang, Min H.
    Billups, Catherine A.
    Collins, Jerry
    Kurmashev, Dias
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2016, 63 (03) : 443 - 450
  • [49] Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program
    Smith, Malcolm A.
    Maris, John M.
    Lock, Richard
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Carol, Hernan
    Morton, Christopher L.
    Reynolds, C. Patrick
    Kang, Min H.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2011, 57 (02) : 268 - 274
  • [50] Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program
    Houghton, Peter J.
    Kang, Min H.
    Reynolds, C. Patrick
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Carol, Hernan
    Lock, Richard
    Maris, John M.
    Billups, Catherine A.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 58 (04) : 636 - 639
12345